CooperCompanies Announces First Quarter 2023 Results

SAN RAMON, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced financial results for its fiscal first quarter ended January 31, 2023.

  • Revenue increased 9% year-over-year to $858.5 million. CooperVision (CVI) revenue up 4% to $581.3 million, and CooperSurgical (CSI) revenue up 23% to $277.2 million.
  • GAAP diluted earnings per share (EPS) of $1.70, down $0.21 or 11% from last year's first quarter.
  • Non-GAAP diluted EPS of $2.90, down $0.34 or 10% from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below.

Commenting on the results, Al White, Cooper's President and CEO said, "We started the year on a positive note with double-digit organic revenue growth and strong operational performances at both CooperVision and CooperSurgical. We're continuing to focus on operational execution combined with prudent investment activity to drive long-term sustainable growth."

First Quarter Operating Results

  • Revenue of $858.5 million, up 9% from last year’s first quarter, up 16% in constant currency, up 10% organically.
  • Gross margin of 65% compared with 66% in last year’s first quarter. On a non-GAAP basis, gross margin was 66%, down from 67% last year driven primarily by currency and product mix.
  • Operating margin of 17% compared with 17% in last year’s first quarter. On a non-GAAP basis, operating margin was 23%, down from 25% last year driven primarily by currency.
  • Interest expense of $26.1 million compared with $6.6 million in last year's first quarter driven by higher interest rates and a higher average debt balance.
  • Net debt outstanding at quarter end was $2.6 billion (total debt excluding unamortized debt issuance costs less cash and cash equivalents) down $47.7 million from last quarter.
  • Cash provided by operations of $166.6 million offset by capital expenditures of $83.0 million resulted in free cash flow of $83.6 million.

First Quarter CooperVision (CVI) Revenue

  • Revenue of $581.3 million, up 4% from last year’s first quarter, up 11% in constant currency, up 10% organically.
  • Revenue by category:
      Constant Currency Organic
  (In millions) % chg % chg % chg
  1Q23 y/y y/y y/y
 Toric$        189.8         4%  11%  11% 
 Multifocal         71.8         9%  17%  17% 
 Single-use sphere         168.3         1%  10%  10% 
 Non single-use sphere, other         151.4         3%  10%  7% 
 Total$        581.3         4%  11%  10% 
  • Revenue by geography:
      Constant Currency Organic
  (In millions) % chg % chg % chg
  1Q23 y/y y/y y/y
 Americas$        241.4         12%  12%  9% 
 EMEA         214.4         —%  11%  12% 
 Asia Pacific         125.5         (5)%  10%  10% 
 Total$        581.3         4%  11%  10% 

First Quarter CooperSurgical (CSI) Revenue

  • Revenue of $277.2 million, up 23% from last year's first quarter, up 26% in constant currency, up 10% organically.
  • Revenue by category:
      Constant Currency Organic
  (In millions) % chg % chg % chg
  1Q23 y/y y/y y/y
 Office and surgical$        165.2         28%  29%  10% 
 Fertility         112.0         16%  23%  10% 
 Total$        277.2         23%  26%  10% 

Fiscal Year 2023 Financial Guidance
The Company updated its fiscal year 2023 financial guidance. Details are summarized as follows:

  • Fiscal 2023 total revenue of $3,496 - $3,553 million (organic growth of 7% to 9%)
    • CVI revenue of $2,352 - $2,388 million (organic growth of 8% to 9%)
    • CSI revenue of $1,144 - $1,166 million (organic growth of 5% to 7%)
  • Fiscal 2023 non-GAAP diluted earnings per share of $12.60 - $12.90

Fiscal year 2023 guidance does not include the Cook Medical Reproductive Health acquisition announced on February 7, 2022, as the transaction is pending regulatory approval.

Non-GAAP diluted earnings per share guidance excludes amortization and impairment of intangible assets, and other exceptional or unusual income or gains and charges or expenses including acquisition, integration and manufacturing related costs which we may incur as part of our continuing operations.

With respect to the Company’s guidance expectations, the Company has not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses, which are reconciling items between the non-GAAP and GAAP measure. Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, the Company is not able to provide such guidance.

Reconciliation of Selected GAAP Results to Non-GAAP Results

To supplement our financial results and guidance presented on a GAAP basis, we use non-GAAP measures that we believe are helpful in understanding our results. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. Management uses supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions. These non-GAAP measures are among the factors management uses in planning and forecasting for future periods. We believe it is useful for investors to understand the effects of these items on our consolidated operating results. Our non-GAAP financial results may include the following adjustments, and as appropriate, the related income tax effects and changes in income attributable to noncontrolling interests:

  • We exclude the effect of amortization and impairment of intangible assets from our non-GAAP financial results. Amortization of intangible assets will recur in future periods; however, the amounts are affected by the timing and size of our acquisitions. Impairment of intangible assets is a non-recurring cost.
  • We exclude the effect of acquisition and integration expenses and the effect of restructuring expenses from our non-GAAP financial results. Such expenses generally diminish over time with respect to past acquisitions; however, we generally will incur similar expenses in connection with any future acquisitions. We incurred significant expenses in connection with our acquisitions and also incurred certain other operating expenses or income, which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. Acquisition and integration expenses include direct effects of acquisition accounting, such as inventory fair value step-up and items such as personnel costs for transitional employees, other acquired employee related costs and integration related professional services. Restructuring expenses include items such as employee severance, product rationalization, facility and other exit costs.
  • We exclude other exceptional or unusual charges or expenses and gains or income. These can be variable and difficult to predict, such as COVID related charges, certain litigation expenses, the gain or loss on deconsolidation of our subsidiaries, changes in fair value of contingent considerations and product transition costs, and are not what we consider as typical of our continuing operations.
  • We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing operations.
  • We exclude the effects of non-cash deferred tax assets related to intra-group transfer of non-inventory assets.

We also report revenue growth using the non-GAAP financial measure of constant currency so that revenue results may be evaluated excluding the effect of foreign currency rate fluctuations. To present this information, current period revenue for entities reporting in currencies other than the United States dollar are converted into United States dollars at the average foreign exchange rates for the corresponding period in the prior year. We also report revenue growth using the non-GAAP financial measure of organic so that revenue results may be evaluated over a comparable period by excluding the effect of foreign currency fluctuations, and excluding the impact of any acquisitions, divestitures, discontinuations that occurred in the comparable period.

We define the non-GAAP measure of free cash flow as cash provided by operating activities less capital expenditures. We believe free cash flow is useful for investors as an additional measure of liquidity because it represents cash that is available to grow the business, make strategic acquisitions, repay debt, buyback common stock or to fund dividend payments. Management uses free cash flow internally to understand, manage, make operating decisions and evaluate our business. In addition, we use free cash flow to help plan and forecast future periods.

We define the non-GAAP measure of net debt as total debt less cash and cash equivalents. We believe net debt is useful for investors to be helpful in evaluating our financial leverage. Management uses net debt as a measure of our financial leverage. Net debt should not be considered as an alternative to debt determined in accordance with GAAP and should be reviewed in conjunction with our consolidated condensed balance sheets.

Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

Reconciliation of Selected GAAP Results to Non-GAAP Results
(In millions, except per share amounts)
  Three Months Ended January 31,
   2023    2023   2022    2022
  GAAP Adjustment Non-GAAP GAAP Adjustment Non-GAAP
Cost of sales $300.0 $(5.7)A$294.3  $268.8 $        (8.2)A$260.6
Operating expense excluding amortization $362.5 $7.5 B$370.0  $345.3 $        (12.5)B$332.8
Amortization of intangibles $46.5 $(46.5)C$  $42.3 $        (42.3)C$
Other expense (income), net $1.3 $(1.8)D$(0.5) $2.3 $        (1.3)D$1.0
Provision for income taxes $37.5 $(13.3)E$24.2  $26.6 $        (1.9)E$24.7
Diluted earnings per share $1.70 $1.20  $2.90  $1.91 $1.33  $3.24
Weighted average diluted shares used  49.7    49.7   49.9    49.9

AFiscal 2023 GAAP cost of sales included $5.7 million of costs primarily related to exit costs of the contact lens care business and integration activities, resulting in fiscal 2023 GAAP gross margin of 65% as compared to fiscal 2023 non-GAAP gross margin of 66%. Fiscal 2022 GAAP cost of sales included $8.2 million of costs primarily related to integration and manufacturing related costs, resulting in fiscal 2022 GAAP gross margin of 66% as compared to fiscal 2022 non-GAAP gross margin of 67%.
BFiscal 2023 GAAP operating expense included a $7.5 million gain due to the release of the remaining $31.8 million contingent consideration liability associated with SightGlass Vision, offset primarily by acquisition and integration activities and severance costs. Fiscal 2022 GAAP operating expense included $12.5 million of costs primarily related to acquisition and integration activities.
CAmortization expense was $46.5 million and $42.3 million for the fiscal 2023 and 2022 periods, respectively. Items A, B, and C resulted in fiscal 2023 GAAP operating margin of 17% as compared to fiscal 2023 non-GAAP operating margin of 23%, and fiscal 2022 GAAP operating margin of 17% as compared to fiscal 2022 non-GAAP operating margin of 25%.
DAdjustments to other expense (income) were primarily related to gains and losses on minority investments.
EAdjustments to provision for income taxes were primarily from the above items and intra-entity asset transfers.

Conference Call and Webcast

The Company will host a conference call today at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1757767. A simultaneous audio webcast can be accessed on CooperCompanies' investor relations website at and a replay will be available shortly after the call on the same website.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 14,000 with products sold in over 100 countries. For more information, please visit

Forward-Looking Statements
This earnings release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including our fiscal year 2023 financial guidance, are forward looking. In addition, all statements regarding anticipated growth in our revenues, anticipated market conditions, planned product launches, restructuring or business transition expectations, regulatory plans, and expected results of operations are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.

Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; the impact of Russia's invasion of Ukraine and the global response to this invasion on the global economy, European economy, financial markets, energy markets, currency rates and our ability to supply product to, or through, affected countries; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our net sales and earnings; our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds; changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income; acquisition-related adverse effects; compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of personal information; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain; market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry specifically and the medical device or pharmaceutical industries generally, including but not limited to the EU Medical Devices Regulation (MDR), and the EU In Vitro Diagnostic Medical Devices Regulation (IVDR); legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes, or other litigation; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions; reduced sales, loss of customers and costs and expenses related to product recalls and warning letters; failure to receive, or delays in receiving, regulatory approvals or certifications for products; failure of our customers and end users to obtain adequate coverage and reimbursement from third-party payors for our products and services; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets and idle manufacturing facilities and equipment; the success of our research and development activities and other start-up projects; dilution to earnings per share from acquisitions or issuing stock; impact and costs incurred from changes in accounting standards and policies; risks related to environmental, social and corporate governance (ESG) issues, including those related to climate change and sustainability; and other events described in our Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2022, as such Risk Factors may be updated in annual and quarterly filings.

We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.


Kim Duncan
Vice President, Investor Relations and Risk Management

Consolidated Condensed Balance Sheets
(In millions)

 January 31, 2023 October 31, 2022
Current assets:   
Cash and cash equivalents$118.2 $138.2
Trade receivables, net 581.8  557.8
Inventories 659.1  628.7
Other current assets 218.4  208.9
Total current assets 1,577.5  1,533.6
Property, plant and equipment, net 1,464.0  1,432.9
Goodwill 3,672.3  3,609.7
Other intangibles, net 1,863.4  1,885.1
Deferred tax assets 2,415.1  2,443.1
Other assets 568.8  587.9
Total assets$11,561.1 $11,492.3
Current liabilities:   
Short-term debt$68.1 $412.6
Accounts Payable 224.1  248.8
Employee compensation and benefits 167.2  152.1
Deferred revenue 106.4  93.6
Other current liabilities 350.0  373.1
Total current liabilities 915.8  1,280.2
Long-term debt 2,627.3  2,350.8
Deferred tax liabilities 144.3  149.9
Long-term tax payable 112.4  113.2
Deferred revenue 195.1  198.3
Accrued pension liability and other 230.5  225.2
Total liabilities 4,225.4  4,317.6
Stockholders’ equity 7,335.7  7,174.7
Total liabilities and stockholders' equity$11,561.1 $11,492.3

Consolidated Statements of Income
(In millions, except per share amounts)

 Three Months Ended January 31,
 2023 2022
Net sales$858.5 $787.2
Cost of sales 300.0  268.8
Gross profit 558.5  518.4
Selling, general and administrative expense 330.9  319.1
Research and development expense 31.6  26.2
Amortization of intangibles 46.5  42.3
Operating income 149.5  130.8
Interest expense 26.1  6.6
Other expense, net 1.3  2.3
Income before income taxes 122.1  121.9
Provision for income taxes 37.5  26.6
Net income$84.6 $95.3
Earnings per share - diluted$1.70 $1.91
Number of shares used to compute diluted earnings per share 49.7  49.9

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.